Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
118 studies found for:    "CINJ" OR "Cancer Intitute of New Jersey" | Open Studies | United States, New Jersey
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
21 Recruiting Talazoparib, Carboplatin, and Paclitaxel in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Condition: Solid Neoplasm
Interventions: Drug: Carboplatin;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Pharmacological Study;   Drug: Talazoparib
Study Type: Interventional
Phase: Phase 1
Funder Type: NIH
Study Design: Allocation: Non-Randomized;   Endpoint Classification: Safety Study;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Number Enrolled: 66
Gender: Both
Age: 18 Years and older   (Adult, Senior)
NCT Number: NCT02317874
22 Not yet recruiting Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery
Conditions: Stage II Prostate Adenocarcinoma;   Stage III Prostate Adenocarcinoma
Interventions: Drug: Abiraterone Acetate;   Drug: Androgen Receptor Antagonist ARN-509;   Biological: Gonadotropin-releasing Hormone Analog;   Drug: Prednisone;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Procedure: Radical Prostatectomy
Study Type: Interventional
Phase: Phase 2
Funder Type: Other / NIH
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Number Enrolled: 90
Gender: Male
Age: Child, Adult, Senior
NCT Number: NCT02949284
23 Recruiting Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG
Condition: Bladder Cancer
Interventions: Biological: TICE Bacillus Calmette-Guerin (BCG);   Biological: PANVAC
Study Type: Interventional
Phase: Phase 2
Funder Type: NIH / Other
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Number Enrolled: 54
Gender: Both
Age: 18 Years to 100 Years   (Adult, Senior)
NCT Number: NCT02015104
24 Recruiting Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer
Conditions: Stage II Non-Small Cell Lung Cancer;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Non-Small Cell Lung Cancer
Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy;   Drug: Carboplatin;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Biological: Pembrolizumab
Study Type: Interventional
Phase: Phase 1
Funder Type: Other / NIH / Industry
Study Design: Endpoint Classification: Safety Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Number Enrolled: 30
Gender: Both
Age: 18 Years and older   (Adult, Senior)
NCT Number: NCT02621398
25 Recruiting Intimacy-Enhancing Couples' Intervention for Localized Prostate Cancer
Conditions: Prostate Cancer;   Sexual Dysfunction and Infertility;   Sexuality
Interventions: Other: communication intervention;   Other: counseling intervention;   Other: nutrition intervention;   Other: questionnaire administration
Study Type: Interventional
Phase:
Funder Type: Other
Study Design: Allocation: Randomized;   Intervention Model: Factorial Assignment;   Masking: Open Label;   Primary Purpose: Supportive Care
Number Enrolled: 372
Gender: Both
Age: 18 Years and older   (Adult, Senior)
NCT Number: NCT01982058
26 Recruiting Chemotherapy Effect on Brain Structure, Neurophysiology and Psychomotor Behavior in Breast Cancer Patients
Condition: Breast Cancer
Interventions: Drug: Exposure: Adjuvant chemotherapy treatment;   Drug: Exposure: Adjuvant hormonal therapy treatment
Study Type: Observational
Phase:
Funder Type: Other
Study Design: Observational Model: Cohort;   Time Perspective: Prospective
Number Enrolled: 60
Gender: Female
Age: 20 Years to 70 Years   (Adult, Senior)
NCT Number: NCT02896504
27 Recruiting Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer
Condition: Malignant Neoplasm
Interventions: Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis
Study Type: Interventional
Phase:
Funder Type: Other / NIH
Study Design: Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Diagnostic
Number Enrolled: 1100
Gender: Both
Age: 1 Year and older   (Child, Adult, Senior)
NCT Number: NCT02688517
28 Recruiting A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF
Condition: Prostate Cancer
Interventions: Biological: pTVG-AR;   Biological: gm-csf
Study Type: Interventional
Phase: Phase 1
Funder Type: Other / NIH
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Number Enrolled: 40
Gender: Male
Age: 18 Years and older   (Adult, Senior)
NCT Number: NCT02411786
29 Recruiting Phase I Study of Intratumoral CAVATAK™ and Pembrolizumab in Subjects With Advanced Melanoma
Condition: Melanoma
Interventions: Biological: CAVATAK;   Drug: Pembrolizumab
Study Type: Interventional
Phase: Phase 1
Funder Type: Industry
Study Design: Endpoint Classification: Safety Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Number Enrolled: 30
Gender: Both
Age: 18 Years and older   (Adult, Senior)
NCT Number: NCT02565992
30 Not yet recruiting A Phase I, Multiple Ascending Dose Study to Assess the Safety and Tolerability of RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD)
Conditions: Malignant Solid Tumor;   Metastatic Cancer;   Advanced Cancer
Interventions: Drug: RRx-001;   Drug: Irinotecan
Study Type: Interventional
Phase: Phase 1
Funder Type: Industry
Study Design: Endpoint Classification: Safety Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Number Enrolled: 24
Gender: Both
Age: 18 Years and older   (Adult, Senior)
NCT Number: NCT02801097
31 Recruiting Psychological Interventions for Gynecologic Cancer
Condition: Gynecologic Cancer
Intervention: Behavioral: Psychotherapy
Study Type: Interventional
Phase:
Funder Type: Other / NIH
Study Design: Allocation: Randomized;   Intervention Model: Factorial Assignment;   Masking: Open Label;   Primary Purpose: Supportive Care
Number Enrolled: 401
Gender: Female
Age: 18 Years and older   (Adult, Senior)
NCT Number: NCT01951807
32 Recruiting Neurophysiological Evaluation of Training Effect on Cancer-Related Weakness
Condition: Breast Cancer
Interventions: Behavioral: Low Intensity Exercise Training 1;   Behavioral: Low Intensity Exercise Training 2
Study Type: Interventional
Phase:
Funder Type: Other / NIH / Industry
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Single Blind (Subject);   Primary Purpose: Treatment
Number Enrolled: 75
Gender: Female
Age: 50 Years to 75 Years   (Adult, Senior)
NCT Number: NCT02844504
33 Recruiting Cytoreductive Prostatectomy in Treating Patients With Newly Diagnosed, Metastatic Prostate Cancer
Conditions: Metastatic Prostate Carcinoma;   Metastatic Prostatic Adenocarcinoma;   Prostate Carcinoma Metastatic to the Bone
Interventions: Procedure: Robotic Assisted Radical Prostatectomy;   Procedure: Conventional open retropubic radical prostectomy;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Drug: ADT (androgen deprivation therapy) (i.e. leuprolide) plus an androgen receptor inhibitor (i.e. bicalutamide)
Study Type: Interventional
Phase: Phase 1
Funder Type: Other / NIH
Study Design: Endpoint Classification: Safety Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Number Enrolled: 50
Gender: Male
Age: 18 Years and older   (Adult, Senior)
NCT Number: NCT02458716
34 Not yet recruiting Phase 1 Two Part Dose Escalation Trial of RRx-001 + Radiation + Temozolomide and RRx-001 + Temozolomide Post-RT In Newly Diagnosed Glioblastoma and Anaplastic Gliomas
Conditions: Glioblastoma;   Oligodendroglioma;   Anaplastic Oligodendroglioma
Interventions: Drug: RRx-001 dose escalation with TMZ + RT;   Radiation: Radiation;   Drug: Fixed dose Temozolomide (75 mg/m2);   Drug: Fixed RRx-001 weekly;   Drug: Staged TMZ and RRx-001 escalation in maintenance stage;   Drug: TMZ Maintenance
Study Type: Interventional
Phase: Phase 1
Funder Type: Industry
Study Design: Allocation: Non-Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Number Enrolled: 39
Gender: Both
Age: 18 Years and older   (Adult, Senior)
NCT Number: NCT02871843
35 Recruiting Autophagy Inhibition to Augment mTOR Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine in Patients With Previously Treated Renal Cell Carcinoma
Conditions: Histological Evidence of Metastatic Clear Cell Renal Cell Carcinoma;   That Has Been Previously Treated With 1-3 Prior Regimens. Phase 1 Only, Any Number of Prior Regimens;   With Evidence of Progressive Disease on or Within 6 Months;   of Discontinuing Sunitinib, Sorafenib or Pazopanib. Previous;   Therapy With Bevacizumab, IL2, or Interferon Are Permitted.
Interventions: Drug: Hydroxychloroquine;   Drug: RAD001
Study Type: Interventional
Phases: Phase 1 / Phase 2
Funder Type: Other
Study Design: Endpoint Classification: Safety/Efficacy Study;   Primary Purpose: Treatment
Number Enrolled: 35
Gender: Both
Age: 18 Years and older   (Adult, Senior)
NCT Number: NCT01510119
36 Recruiting A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis
Condition: Desmoid Tumor
Intervention: Drug: Sirolimus
Study Type: Interventional
Phases: Phase 1 / Phase 2
Funder Type: Other
Study Design: Endpoint Classification: Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Number Enrolled: 15
Gender: Both
Age: up to 29 Years   (Child, Adult)
NCT Number: NCT01265030
37 Recruiting Dose-Escalation Study of RRx-001 in Combination With Whole Brain Radiation in Subjects With Brain Metastases
Condition: Brain Metastases
Intervention: Drug: RRx-001 + WBRT
Study Type: Interventional
Phase: Phase 1
Funder Type: Industry
Study Design: Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Number Enrolled: 30
Gender: Both
Age: 18 Years and older   (Adult, Senior)
NCT Number: NCT02215512
38 Recruiting Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer
Condition: Prostate Cancer
Interventions: Radiation: Proton Beam Therapy;   Radiation: Intensity Modulated Radiation Therapy
Study Type: Interventional
Phase: Phase 3
Funder Type: Other / NIH
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Number Enrolled: 400
Gender: Male
Age: 18 Years and older   (Adult, Senior)
NCT Number: NCT01617161
39 Recruiting Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Conditions: Stage IB Non-Small Cell Lung Carcinoma;   Stage IIA Non-Small Cell Lung Carcinoma;   Stage IIB Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer
Interventions: Drug: Crizotinib;   Other: Laboratory Biomarker Analysis;   Other: Placebo
Study Type: Interventional
Phase: Phase 3
Funder Type: Other / NIH
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Investigator);   Primary Purpose: Treatment
Number Enrolled: 378
Gender: Both
Age: 18 Years and older   (Adult, Senior)
NCT Number: NCT02201992
40 Recruiting Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Conditions: Large Cell Lung Carcinoma;   Lung Adenocarcinoma;   Stage IB Non-Small Cell Lung Carcinoma;   Stage IB Squamous Cell Lung Carcinoma;   Stage IIA Non-Small Cell Lung Carcinoma;   Stage IIA Squamous Cell Lung Carcinoma;   Stage IIB Non-Small Cell Lung Carcinoma;   Stage IIB Squamous Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIA Squamous Cell Lung Carcinoma
Interventions: Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis
Study Type: Observational
Phase:
Funder Type: NIH
Study Design:
Number Enrolled: 8300
Gender: Both
Age: 18 Years and older   (Adult, Senior)
NCT Number: NCT02194738

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.